Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
100% ORR and MRD-negative responses observed in all evaluable patients, earliest dosed patients remain in ongoing MRD negative response beyond 9 months
Favorable safety profile consistent with outpatient dosing
13-day median time from consent to infusion
CAR-T cell expansion and persistence in the absence of lymphodepleting chemotherapy
